Once the diagnosis became clear, the questions changed from “What is this?” to “What do we do about it?”
There is no single treatment path that applies to every person with Sézary syndrome. My doctors have discussed treatment in terms of controlling the disease, getting it into the best remission possible and determining whether I can ultimately proceed to an allogeneic stem-cell transplant.
My current treatment
The first systemic treatment selected for me is mogamulizumab, often shortened to MOGA. It is given by IV and is intended to target the malignant T cells. My team has explained that response is not necessarily immediate; we will be watching the blood, skin, lymph nodes, symptoms and future imaging to understand how well it is working.
Other therapies have also entered the discussion, including medicines used specifically in CTCL and treatments aimed at the skin. The sequence matters because the larger strategy may include transplant, and some treatments require a washout period before that can happen.
How the MOGA course will be judged
My first cycle of mogamulizumab consists of four weekly infusions. The next dose comes one week after the fourth infusion, beginning the every-other-week schedule. After that, treatments continue every other week. In practical terms, that means the first five infusions are each one week apart before the spacing changes to every other week. My team expects treatment to continue for at least six months if it is working and I am tolerating it, although the exact duration will depend on how quickly and completely the disease responds.
The routine blood counts will be checked with treatment, while the more detailed flow cytometry that measures the abnormal T-cell population will be repeated about every two to three months. The hope is that the malignant cells in the blood become undetectable within roughly the first three months.
Blood response is only part of the picture. My doctors also want to know whether the skin, lymph nodes and the lymphoma deposits beneath the skin are responding. We are planning another scan at about the three-month point. If the blood clears but the lymph nodes or subcutaneous disease remain stubborn, the treatment strategy may need to change or additional therapy may be added.
If everything responds rapidly, the significance goes beyond simply showing that MOGA works. The speed and completeness of that response may help determine whether I proceed directly toward stem-cell transplant or whether there is reason to pause and reconsider that timing.
What I want to document
Medical descriptions tell you what a drug is supposed to do. I want this section to record the other half: how long an infusion takes, what the days afterward feel like, whether the itching changes, what happens to the skin, what blood tests show, and how treatment affects normal life.
I will update this page as the treatment plan changes. The dated Journal will contain the detailed entries; this page will become the organized overview of the treatment course.
